We are live on ! Find out more
CALA

Calithera Biosciences, Inc

Delisted

CALA was delisted on the 1st of February, 2023.

90 hedge funds and large institutions have $100M invested in Calithera Biosciences, Inc in 2018 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 25 increasing their positions, 33 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

10% less funds holding

Funds holding: 10090 (-10)

24% less repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 33

26% less call options, than puts

Call options by funds: $535K | Put options by funds: $720K

29% less capital invested

Capital invested by funds: $142M → $100M (-$41.9M)

38% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 26

Holders
90
Holders Change
-10
Holders Change %
-10%
% of All Funds
2.06%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
16
Increased
25
Reduced
33
Closed
26
Calls
$535K
Puts
$720K
Net Calls
-$185K
Net Calls Change
+$202K
Name Holding Trade Value Shares
Change
Change in
Stake
TCIM
26
TIAA CREF Investment Management
New York
$564K -$87.6K -773 -12%
Goldman Sachs
27
Goldman Sachs
New York
$554K -$441K -3,893 -41%
HP
28
Hikari Power
Japan
$500K +$566K +5,000 New
Citadel Advisors
29
Citadel Advisors
Florida
$476K +$122K +1,078 +29%
CM
30
Crestline Management
Texas
$435K +$152K +1,343 +45%
Jacobs Levy Equity Management
31
Jacobs Levy Equity Management
New Jersey
$431K +$157K +1,388 +47%
FSA
32
Franklin Street Advisors
North Carolina
$408K -$28.3K -250 -6%
Charles Schwab
33
Charles Schwab
California
$345K -$323K -2,850 -45%
Morgan Stanley
34
Morgan Stanley
New York
$339K -$5.89K -52 -2%
Bank of America
35
Bank of America
North Carolina
$330K +$17.1K +151 +5%
Wells Fargo
36
Wells Fargo
California
$329K +$1.36K +12 +0.4%
T. Rowe Price Associates
37
T. Rowe Price Associates
Maryland
$329K +$24.4K +215 +7%
CAM
38
ClariVest Asset Management
California
$307K -$53.1K -469 -13%
Squarepoint
39
Squarepoint
New York
$293K -$53.9K -476 -14%
USAA
40
United Services Automobile Association
Texas
$275K -$3.96K -35 -1%
New York State Common Retirement Fund
41
New York State Common Retirement Fund
New York
$274K +$125K +1,100 +67%
AA
42
ALPS Advisors
Colorado
$260K +$25.2K +222 +9%
California State Teachers Retirement System (CalSTRS)
43
California State Teachers Retirement System (CalSTRS)
California
$237K
Acadian Asset Management
44
Acadian Asset Management
Massachusetts
$208K -$178K -1,571 -43%
PCM
45
Piermont Capital Management
Missouri
$192K +$218K +1,920 New
RhumbLine Advisers
46
RhumbLine Advisers
Massachusetts
$159K +$21.6K +191 +14%
AllianceBernstein
47
AllianceBernstein
Tennessee
$152K +$11.9K +105 +7%
TRSOTSOK
48
Teachers Retirement System of the State of Kentucky
Kentucky
$138K
JG
49
Jefferies Group
New York
$137K +$155K +1,371 New
State of Wisconsin Investment Board
50
State of Wisconsin Investment Board
Wisconsin
$115K

CALA Hedge Fund Activity: Q2 2018 in Review

90 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Calithera Biosciences, Inc (CALA) for Q2 2018, worth a combined $100M — down 29% from $142M a quarter earlier.

Sellers outnumbered buyers: 26 funds closed out of CALA and 16 opened new positions — a net loss of 10 holders — while 33 trimmed existing stakes and 25 added.

The largest buyer was Federated Hermes, adding an estimated $2.64M. The largest seller was Fidelity Investments, exiting entirely with an estimated $4.29M sold.

  • 90 institutional investors held Calithera Biosciences, Inc (CALA) as of Q2 2018, down from 100 in Q1 2018.
  • Funds reported $100M of Calithera Biosciences, Inc stock for Q2 2018, down 29% quarter-over-quarter.
  • 16 funds opened new Calithera Biosciences, Inc positions in Q2 2018 and 26 closed out, a net change of -10 holders.
  • The largest Calithera Biosciences, Inc buyer in Q2 2018 was Federated Hermes, an estimated $2.64M added.
  • The largest Calithera Biosciences, Inc seller in Q2 2018 was Fidelity Investments, an estimated $4.29M sold.

Based on aggregated 13F filings for Q2 2018.